# Empagliflozin Versus Linagliptin in Renal Ransplant Recipients With Diabetes Mellitus

> **NCT06098625** · NA · UNKNOWN · sponsor: **Medanta, The Medicity, India** · enrollment: 200 (estimated)

## Conditions studied

- Diabetes Mellitus
- Kidney Transplant; Complications

## Interventions

- **DRUG:** Empagliflozin 25 MG
- **DRUG:** Linagliptin 5 mg Oral Tablet

## Key facts

- **NCT ID:** NCT06098625
- **Lead sponsor:** Medanta, The Medicity, India
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-11-10
- **Primary completion:** 2025-07-01
- **Final completion:** 2025-12-01
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2023-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06098625

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06098625, "Empagliflozin Versus Linagliptin in Renal Ransplant Recipients With Diabetes Mellitus". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT06098625. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*